PRODUCT MONOGRAPH
SAXENDA® (liraglutide) Page 1 of 47. PRODUCT MONOGRAPH. SAXENDA®. liraglutide . 6 mg/mL . Solution for Injection in a pre-filled pen . Human Glucagon Like Peptide-1 (GLP-1) Weight Management
Download PRODUCT MONOGRAPH
Information
Domain:
Source:
Link to this page:
Documents from same domain
New fast-acting mealtime insulin, Fiasp , now …
www.novonordisk.caNew fast-acting mealtime insulin, Fiasp ®, now approved and available in Canada for the treatment of diabetes . Faster absorption of insulin key for Canadians living with diabetes
![[Product Monograph Template - Schedule D]](/cache/preview/b/f/c/5/9/9/f/5/thumb-bfc599f58969b8bff3fb0f7d9d95ed1e.jpg)
[Product Monograph Template - Schedule D]
www.novonordisk.caTRESIBA® (insulin degludec injection) -Product Monograph Page 2 of 64. Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION..... 3 SUMMARY PRODUCT INFORMATION.....
![[Product Monograph Template - Schedule D]](/cache/preview/d/4/6/e/b/1/2/5/thumb-d46eb12554b4ea3c3e73eb4fb39cc2d4.jpg)
[Product Monograph Template - Schedule D]
www.novonordisk.cadisodium phosphate dihydrate, propylene glycol, phenol, and water for injections.
![[Product Monograph Template - Standard]](/cache/preview/f/9/7/c/8/1/3/1/thumb-f97c8131495ab4887eae21b91c1e72e4.jpg)
[Product Monograph Template - Standard]
www.novonordisk.caPRODUCT MONOGRAPH PrVagifem® 10 Estradiol vaginal inserts USP, 10 µg estradiol Vaginal inserts with applicators Estrogen Novo Nordisk Canada Inc. …
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR …
www.novonordisk.caNovoRapid® - Product Monograph Page 35 of 49 injections. Consult your doctor if you are planning such travel. Are pregnant, or planning a pregnancy or are breastfeeding please contact your doctor for advice.
PRODUCT MONOGRAPH INCLUDING PATIENT …
www.novonordisk.caFiasp® Product Monograph Page 1 of 46. PRODUCT MONOGRAPH. INCLUDING PATIENT MEDICATION INFORMATION . Fiasp®. insulin aspart injection . Solution, 100 U/mL, subcutaneous use . House Standard
PRODUCT MONOGRAPH Schedule D - novonordisk.ca
www.novonordisk.caNovolin®ge 50/50 are a series of Insulin, Human Biosynthetic mixtures containing Novolin®ge Toronto and Novolin®ge NPH, respectively, in the proportions indicated by the ratio in the product name.
New fast-acting mealtime insulin, Fiasp , now approved and ...
www.novonordisk.caNew fast-acting mealtime insulin, Fiasp ®, now approved and available in Canada for the treatment of diabetes . Faster absorption of insulin key for Canadians living with diabetes
PRODUCT MONOGRAPH INCLUDING PATIENT …
www.novonordisk.caProduct Monograph OZEMPIC® semaglutide injection Page 1 of 56. PRODUCT MONOGRAPH . INCLUDING PATIENT MEDICATION INFORMATION . PROZEMPIC® semaglutide injection . 2 mg/pen (1.34 mg/mL) 4 mg/pen (1.34 mg/mL) Pre-filled pen delivering doses of 0.25 mg or 0.5 mg . and . Pre-filled pen delivering doses of 1 mg . ATC code: A10BJ06 ...
NovoRapid - Novo Nordisk
www.novonordisk.calisting, see DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING. ... • Some insulin products are short-acting insulin and are known for their rapid onset and short duration of action. The injection of such insulin products should immediately be followed by a meal (within 5-10 minutes or given immediately after ...
Related documents
医薬品安全性情報 Vol.11 No.04 2013/02/14
www.nihs.go.jp[‘Pico-Salax’]は，浸透圧性緩下剤として作用し，蠕動を刺激して服用から3～6時間以内に強 力な「洗浄」作用を現す
September 2017 Drug Information Update - PerformRx
www.performrx.comCopyright© PerformRx, LLC 2017 All Rights Reserved. 9 Healthcare professionals and patients are encouraged to report adverse events or side effects related to
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.novo-pi.com1 ——— CONTRAINDICATIONS ——— VICTOZA® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (4). VICTOZA® is contraindicated in patients with a prior serious hypersensitivity reaction to VICTOZA® or any of the product components (4).
HIGHLIGHTS OF PRESCRIBING INFORMATION - novo-pi.com
www.novo-pi.comXultophy ® 100/3.6 (insulin egludec nd iraglutide injection) 2 FULL PRESCRIBING INFORMATION WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide, one of the components of XULTOPHY® 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically